Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “HALOZYME, INC.”

69 pharma patents match "HALOZYME, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 69
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 69 pharmaceutical patents matching "HALOZYME, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

69 results for “HALOZYME, INC.” · 30,257 patents in full index Clear search

  1. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    HALOZYME, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted

  2. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted

  3. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted

  4. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    HALOZYME, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted

  5. US 12152262

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted

  6. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted

  7. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted

  8. US 12104184

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted

  9. US 12104185

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted

  10. US 12091692

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted

  11. US 12077791

    PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof

    HALOZYME, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted

  12. US 12060590

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted

  13. US 12054758

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted

  14. US 12049652

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted

  15. US 12037618

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted

  16. US 12018298

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted

  17. US 11952600

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted

  18. US 11723959

    Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide

    HALOZYME, INC. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted

  19. US 11584923

    Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

    HALOZYME, INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  20. US 11414489

    Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

    HALOZYME, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  21. US 11066656

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  22. US 11041149

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted

  23. US 10898551

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    HALOZYME, INC. · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted

  24. US 10865400

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.